Table 1.
Relationship between PLCɛ expression and the clinicopathological parameters in prostate cancer patients.
| Numbers | Number of patients (%) | P-value | ||
|---|---|---|---|---|
| Positive | Negative | |||
| Total number | 40 | 36 (90.00) | 4 (10.00) | |
| Age (year) | ||||
| <60 | 13 (32.50) | 10 (27.77) | 3 (75.00) | 0.056 |
| ≥60 | 27 (67.50) | 26 (72.23) | 1 (25.00) | |
| Histological stage | ||||
| Ta–T1 | 19 (47.50) | 15 (41.66) | 4 (100) | 0.027* |
| T2–T4 | 21 (52.50) | 21 (58.33) | 0 (0) | |
| Gleason grade | ||||
| <7 | 11 (27.50) | 10 (41.66) | 1 (25.00) | 0.906 |
| ≥7 | 29 (72.50) | 26 (58.33) | 3 (75.00) | |
*
Statistically significant.